This preclinical study demonstrates that the liver actively takes up and degrades lipoprotein lipase via specific binding sites, which facilitates hepatic utilization of triacylglycerol emulsions.
Answers are grounded in this paper and cite their sources.
Supports hepatic LPL uptake in rat TG handling; leaves open relevance to human lipoprotein metabolism.
We have studied the binding and metabolism of 125I-labeled bovine lipoprotein lipase (LPL) by use of isolated, perfused rat livers. Our data suggest the presence of two types of binding sites, i.e., heparin-sensitive sites that bind primarily the catalytically active form of the lipase and are present at the endothelium in all blood vessels and heparin-insensitive sites that bind both active and inactive forms and are present only within the sinusoids. Forty minutes after uptake by the liver, approximately 50% of the LPL had lost its catalytic activity or been degraded. Three processes were evident: 1) colchicine-sensitive degradation to acid-soluble products, 2) partial proteolysis to fragments similar to those formed by limited digestion with trypsin or plasmin, and 3) a conformational change leading to loss of catalytic activity. Exogenous LPL bound in the liver caused a dramatic increase in the utilization of a perfused triacylglycerol emulsion (Intralipid), with rapid formation of free fatty acids and water-soluble metabolites. When the liver was flushed with heparin, it lost its ability to utilize the fat emulsion. Measurement of the hepatic extraction showed that rat livers take up 100-200 mU endogenous LPL per hour.
No takes yet. Share an insight, caveat, or question.
Vilaró et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: